Allied Market Research
Loading...
Cart
0
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

New
New Allied Market Research

Telmisartan Market by Indication (Hypertension and Cardiovascular Risk Reduction) and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2020–2027

A10293
Pages: 225
Feb 2021 | 607 Views
 
Author(s) : Sagar Mukhekar, Sushant Terdale , Onkar Sumant
Tables: 22
Charts: 19
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Telmisartan Market

Request Now !

Telmisartan Market Statistics 2020-2027:

The global telmisartan market size was valued at $3,453 million in 2019, and is projected to reach $4,258 million by 2027, registering a CAGR of 3.4% from 2020 to 2027.

Telmisartan drug is a non-peptide angiotensin receptor blockers (ARBs) intended for treatment of hypertension and cardiovascular risk reduction. It is used alone or in combination with other agents such as hydrochlorothiazide and amlodipine. Telmisartan is available in three different strengths tablets such as 20 mg, 40 mg, and 80 mg. Telmisartan is indicated for the treatment of mild to moderate hypertension condition. It works by relaxing blood vessels so that blood can flow more easily. However, it has some side effects which include dizziness, cough, lightheadedness, sinus pain and others.

Telmisartan-Market,-2020-2027

Get more information on this report : Request Sample Pages

Increase in prevalence of high blood pressure (hypertension), surge in geriatric population, and rise in government initiatives for spreading awareness about blood pressure diseases are the factors that are expected to drive the growth of the market. For instance, in May 2017, Argentinian Society of Hypertension (SAHA) joined in campaigns such as ‘May Measurement Month & World Hypertension Day’ for making awareness among population about hypertension and its management. In addition, rise in marketing approvals for generic versions of telmisartan, increase in sedentary lifestyle, and surge in incidences of chronic diseases such as diabetes and kidney disease, are expected to drive the growth of the telmisartan market. However, drug shortages are expected to restrain the growth of the telmisartan market. Conversely, surge in research related to telmisartan drug in emerging economies is expected to offer lucrative opportunities during the forecast period.

The World Health Organization (WHO) on January 30, 2020, declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. Telmisartan tablets manufacturing and distributing companies have been affected by COVID-19 to a limited extent, owing to shut down in various COVID-19 affected countries and rise in number of healthcare workers falling ill in the wake of the COVID-19 pandemic, leading to supply shortage.

Telmisartan Market Segmentation  

The global telmisartan market is segmented into indication, distribution channel, and region. On the basis of indication, the market is categorized into hypertension and cardiovascular risk reduction. Depending on distribution channel, it is segregated into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Telmisartan Market
By Indication

Your browser does not support the canvas element.

Hypertension segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Telmisartan Market Segment review 

Presently, on the basis of indication, the hypertension is a major revenue contributor, and is projected to grow significantly during the forecast period. Increase in prevalence of hypertension, rise in demand for antihypertensive drugs, and surge in awareness about hypertension and its management by organizing global level campaigns boosts the growth of the market. Moreover, availability of better treatment options for hypertension, increase in number of product approvals, and rise in geriatric population suffering from hypertension are the other factors that drive the growth of the market.

Depending on distribution channel, the hospital pharmacies segment is the major shareholder in the global telmisartan market, owing to surge in number of hospitalized hypertension patients, increase in number of hospital pharmacies worldwide, and improvement in structure of hospital pharmacies in the emerging countries such as China and India. Moreover, telmisartan drug is a prescription-based medication, which is mostly prescribed by the specialized healthcare professionals available in hospitals, thereby boosting the growth of this segment. On the contrary, the online pharmacies segment is expected to exhibit the highest growth rate during the forecast period, owing to increase in awareness of online pharmacy, rise in preference for online purchasing of drugs, and surge in the use of internet across the globe. Moreover, online pharmacies offer various advantages such as more convenience, fewer expenses, easy access to patient reviews, and price comparisons, which drive the market growth.

Telmisartan Market
By Distribution Channel

Your browser does not support the canvas element.

Hospital Pharmacies segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Snapshot of Asia-Pacific telmisartan market  

Asia-Pacific presents lucrative opportunities for key players operating in the telmisartan market, owing to increase in number of hypertension patients in emerging economies, rise in adoption of antihypertensive drugs, development of the R&D sector, rise in healthcare reforms, and technological advancements in pharmaceutical drug manufacturing, Moreover, rise in demand for telmisartan tablets, surge in funding from government and non-government sectors to create awareness about hypertension and cardiovascular diseases, rise in number of hospital pharmacies and online pharmacies, and presence of high population base contributes toward growth of the market. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive the growth of the telmisartan market in the region.

The key players profiled in this report include Abbott Laboratories, Aurobindo Pharma, Boehringer Ingelheim International GmbH, Cipla Inc., Glaxosmithkline Plc (GSK), Mylan N.V., Sanofi, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd. (Actavis Generics), and Zydus Cadila.

Telmisartan Market
By Region

2027
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 5.2% during 2019-2026.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the telmisartan market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers telmisartan market analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global telmisartan market growth.

Key Market Segments

By Indication

  • Hypertension 
  • Cardiovascular Risk Reduction

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China 
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five force analysis
3.4.Top player positioning, 2019
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Surge in geriatric population worldwide
3.5.1.2.Increase in healthcare expenditure worldwide coupled with surge in awareness towards treatment of high blood pressure
3.5.1.3.Rise in prevalence of hypertension across the globe

3.5.2.Restraint

3.5.2.1.Drug shortages of telmisartan tablets

3.5.3.Opportunities

3.5.3.1.High growth potential in developing economies

3.5.4.Impact analysis

3.6.Covid-19 Impact analysis on telmisartan market

CHAPTER 4:TELMISARTAN MARKET, BY INDICATION

4.1.Overview

4.1.1.Market size and forecast

4.2.Hypertension

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Cardiovascular risk reduction

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

CHAPTER 5:TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospital pharmacies

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Drug stores and retail pharmacies

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Online pharmacies

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:TELMISARTAN MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by country

6.2.2.1.U.S.

6.2.2.1.1.U.S. telmisartan market, by indication
6.2.2.1.2.U.S. telmisartan market, by distribution channel

6.2.2.2.Canada

6.2.2.2.1.Canada telmisartan market, by indication
6.2.2.2.2.Canada telmisartan market, by distribution channel

6.2.2.3.Mexico

6.2.2.3.1.Mexico telmisartan market, by indication
6.2.2.3.2.Mexico telmisartan market, by distribution channel
6.2.3.North America market size and forecast, by indication
6.2.4.North America market size and forecast, by distribution channel

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by country

6.3.2.1.Germany

6.3.2.1.1.Germany telmisartan market, by indication
6.3.2.1.2.Germany telmisartan market, by distribution channel

6.3.2.2.France

6.3.2.2.1.France telmisartan market, by indication
6.3.2.2.2.France telmisartan market, by distribution channel

6.3.2.3.UK

6.3.2.3.1.UK telmisartan market, by indication
6.3.2.3.2.UK telmisartan market, by distribution channel

6.3.2.4.Italy

6.3.2.4.1.Italy telmisartan market, by indication
6.3.2.4.2.Italy telmisartan market, by distribution channel

6.3.2.5.Spain

6.3.2.5.1.Spain telmisartan market, by indication
6.3.2.5.2.Spain telmisartan market, by distribution channel

6.3.2.6.Rest of Europe

6.3.2.6.1.Rest of Europe telmisartan market, by indication
6.3.2.6.2.Rest of Europe telmisartan market, by distribution channel

6.3.3.Europe market size and forecast, by indication
6.3.4.Europe market size and forecast, by distribution channel

6.4.Asia-Pacific

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by country

6.4.2.1.Japan

6.4.2.1.1.Japan telmisartan market, by indication
6.4.2.1.2.Japan telmisartan market, by distribution channel

6.4.2.2.China

6.4.2.2.1.China telmisartan market, by indication
6.4.2.2.2.China telmisartan market, by distribution channel

6.4.2.3.Australia

6.4.2.3.1.Australia telmisartan market, by indication
6.4.2.3.2.Australia telmisartan market, by distribution channel

6.4.2.4.India

6.4.2.4.1.India telmisartan market, by indication
6.4.2.4.2.India telmisartan market, by distribution channel

6.4.2.5.South Korea

6.4.2.5.1.South Korea telmisartan market, by indication
6.4.2.5.2.South Korea telmisartan market, by distribution channel

6.4.2.6.Rest of Asia-Pacific

6.4.2.6.1.Rest of Asia-Pacific telmisartan market, by indication
6.4.2.6.2.Rest of Asia-Pacific telmisartan market, by distribution channel

6.4.3.Asia-Pacific market size and forecast, by indication
6.4.4.Asia-Pacific market size and forecast, by distribution channel

6.5.LAMEA

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by country

6.5.2.1.Brazil

6.5.2.1.1.Brazil telmisartan market, by indication
6.5.2.1.2.Brazil telmisartan market, by distribution channel

6.5.2.2.Saudi Arabia

6.5.2.2.1.Saudi Arabia telmisartan market, by indication
6.5.2.2.2.Saudi Arabia telmisartan market, by distribution channel

6.5.2.3.South Africa

6.5.2.3.1.South Africa telmisartan market, by indication
6.5.2.3.2.South Africa telmisartan market, by distribution channel

6.5.2.4.Rest of LAMEA

6.5.2.4.1.Rest of LAMEA telmisartan market, by indication
6.5.2.4.2.Rest of LAMEA telmisartan market, by distribution channel

6.5.3.LAMEA market size and forecast, by indication
6.5.4.LAMEA market size and forecast, by distribution channel

CHAPTER 7:COMPANY PROFILES

7.1.ABBOTT LABORATORIES

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.AUROBINDO PHARMA

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance.

7.3.BOEHRINGER INGELHEIM INTERNATIONAL GMBH

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance

7.4.CIPLA INC.

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance

7.5.GLAXOSMITHKLINE PLC (GSK)

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance.

7.6.MYLAN N.V.

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance

7.7.SANOFI

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance

7.8.SUN PHARMACEUTICAL INDUSTRIES LIMITED

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance

7.9.TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance

7.10.ZYDUS CADILA

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance.
7.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL TELMISARTAN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 02.TELMISARTAN MARKET FOR HYPERTENSION, BY REGION, 2019–2027 ($MILLION)
TABLE 03.TELMISARTAN MARKET FOR CARDIOVASCULAR RISK REDUCTION, BY REGION, 2019–2027 ($MILLION)
TABLE 04.TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 05.HOSPITAL PHARMACIES TELMISARTAN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 06.DRUG STORES AND RETAIL PHARMACIES TELMISARTAN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 07.ONLINE PHARMACIES TELMISARTAN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 08.TELMISARTAN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 09.NORTH AMERICA TELMISARTAN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 10.U.S. TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 11.U.S. TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 12.CANADA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 13.CANADA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 14.MEXICO TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 15.MEXICO TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 16.NORTH AMERICA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 17.NORTH AMERICA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 18.EUROPE TELMISARTAN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 19.GERMANY TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 20.GERMANY TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 21.FRANCE TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 22.FRANCE TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 23.UK TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 24.UK TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 25.ITALY TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 26.ITALY TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 27.SPAIN TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 28.SPAIN TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 29.REST OF EUROPE TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 30.REST OF EUROPE TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 31.EUROPE TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 32.EUROPE TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 33.ASIA-PACIFIC TELMISARTAN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 34.JAPAN TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 35.JAPAN TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 36.CHINA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 37.CHINA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 38.AUSTRALIA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 39.AUSTRALIA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 40.INDIA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 41.INDIA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 42.SOUTH KOREA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 43.SOUTH KOREA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 44.REST OF ASIA-PACIFIC TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 45.REST OF ASIA-PACIFIC TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 46.ASIA-PACIFIC TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 47.ASIA-PACIFIC TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 48.LAMEA TELMISARTAN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 49.BRAZIL TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 50.BRAZIL TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 51.SAUDI ARABIA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 52.SAUDI ARABIA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 53.SOUTH AFRICA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 54.SOUTH AFRICA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 55.REST OF LAMEA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 56.REST OF LAMEA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 57.LAMEA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 58.LAMEA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 59.ABBOTT: COMPANY SNAPSHOT
TABLE 60.ABBOTT: OERATING SEGMENT
TABLE 61.ABBOTT: PRODUCT PORTFOLIO
TABLE 62.AUROBINDO: COMPANY SNAPSHOT
TABLE 63.AUROBINDO: PRODUCT PORTFOLIO
TABLE 64.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 65.BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 66.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 01.CIPLA: COMPANY SNAPSHOT
TABLE 02.CIPLA: OPERATING SEGMENTS
TABLE 03.CIPLA: PRODUCT PORTFOLIO
TABLE 04.GSK: COMPANY SNAPSHOT
TABLE 05.GSK: OPERATING SEGMENTS
TABLE 06.GSK: PRODUCT PORTFOLIO
TABLE 07.MYLAN: COMPANY SNAPSHOT
TABLE 08.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 09.MYLAN: PRODUCT PORTFOLIO
TABLE 10.SANOFI: COMPANY SNAPSHOT
TABLE 11.SANOFI: OERATING SEGMENT
TABLE 12.SANOFI: PRODUCT PORTFOLIO
TABLE 13.SUN PHARMA: COMPANY SNAPSHOT
TABLE 14.SUN PHARMA: OPERATING SEGMENTS
TABLE 15.SUN PHARMA: PRODUCT PORTFOLIO
TABLE 16.TEVA: COMPANY SNAPSHOT
TABLE 17.TEVA: OPERATING SEGMENTS
TABLE 18.TEVA: PRODUCT PORTFOLIO
TABLE 19.ZYDUS: COMPANY SNAPSHOT
TABLE 20.ZYDUS: OPERATING SEGMENTS
TABLE 21.ZYDUS: PRODUCT PORTFOLIO
TABLE 22.ZYDUS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.GLOBAL TELMISARTAN MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
FIGURE 03.LOW THREAT OF SUBSTITUTES
FIGURE 04.HIGH THREAT OF NEW ENTRANTS
FIGURE 05.MODERATE INTENSITY OF RIVALRY
FIGURE 06.TOP PLAYER POSITIONING, 2019
FIGURE 07.IMPACT ANALYSIS
FIGURE 08.COMPARATIVE ANALYSIS OF TELMISARTAN MARKET FOR HYPERTENSION, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 09.COMPARATIVE ANALYSIS OF TELMISARTAN MARKET FOR CARDIOVASCULAR RISK REDUCTION, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 10.COMPARATIVE ANALYSIS OF HOSPITAL PHARMACIES TELMISARTAN MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES TELMISARTAN MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF ONLINE PHARMACIES TELMISARTAN MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 13.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 14.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 15.ABBOTT: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 16.AUROBINDO: NET SALES, 2018–2020 ($MILLION)
FIGURE 17.AUROBINDO: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 18.BOEHRINGER INGELHEIM: NET SALES, 2017–2019 ($MILLION)
FIGURE 19.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 20.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 01.CIPLA: NET SALES, 2017–2019 ($MILLION)
FIGURE 02.CIPLA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 03.CIPLA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 04.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 05.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 06.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 07.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 08.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 09.SANOFI.: NET SALES, 2017–2019 ($MILLION)
FIGURE 10.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 11.SANOFI: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 12.SUN PHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 13.SUN PHARMA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 14.TEVA: NET SALES, 2017–2019 ($MILLION)
FIGURE 15.TEVA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 16.TEVA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 17.ZYDUS: NET SALES, 2018–2020 ($MILLION)
FIGURE 18.ZYDUS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 19.ZYDUS: REVENUE SHARE, BY REGION, 2020 (%)

 
 

Telmisartan is an angiotensin receptor blocker (ARB) used alone or in combination with hydrochlorothiazide and amlodipine for treatment of hypertension and cardiovascular risk reduction. It is available in different strengths tablets such as 20 mg, 40 mg, and 80 mg.

The utilization of telmisartan drug has witnessed significant growth, owing to surge in incidence of hypertension and cardiovascular diseases worldwide. Furthermore, other factors such as rise in geriatric population suffering from high blood pressure, surge in generic telmsartan tablets approvals, surge in awareness related to complication of hypertension, and sedentary lifestyle are the factors that fuel the growth of the market. However, drug shortages are expected to restrain the growth of the telmisartan market.

 
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. Telmisartan is indicated for the treatment of mild to moderate hypertension and cardiovascular risk reduction.

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 6.0%. This is due to increase in number of hypertension patients in emerging economies, rise in adoption of antihypertensive drugs, development of the R&D sector, rise in healthcare reforms, and technological advancements in pharmaceutical drug manufacturing, Moreover, rise in demand for telmisartan tablets, and surge in funding from government and non-government sectors to create awareness about hypertension and cardiovascular diseases.

A. The total market value of Telmisartan market is $3,453.13 million in 2019.

A. The forcast period for Telmisartan market is 2020 to 2027

A. Top companies such as Abbott Laboratories, Boehringer Ingelheim International GmbH, Glaxosmithkline Plc (GSK), Mylan N.V., Teva Pharmaceutical Industries Ltd. (Actavis Generics), and Zydus Cadila held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. The market value of Telmisartan market in 2020 is $3,366.81 million.

A. Hypertension segment is the most influencing segment owing to surge in prevalence of hypertension across the globe, rise in awareness related to the use of telmisartan for the treatment of high blood pressure.

A. The base year is 2019 in Telmisartan market

A. The growth of the global telmisartan market is driven by surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension and cardiovascular is another major factor that fuels the growth of the market. In addition, surge in geriatric population and sedentary lifestyle act as key drivers of the global market. Moreover, increase in approval for abbreviated new drug application (ANDA) for manufacturing of generic telmisartan tablets and rise in cases of chronic kidney disease is expected to propel growth of telmisartan market.

Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Telmisartan Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers